Search clinical trials for: secukinumab 150 mg

Total 16380 results

Novartis Pharmaceuticals

Completed

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque-type Psoriasis

United States, Hungary, Italy, Russian Federation, Germany, Czechia, Canada
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Japan
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year (ERASURE)

Moderate to Severe Plaque-type Psoriasis

United States, Colombia, Estonia, Japan, Taiwan, Israel, Canada, Lithuania, Argentina, Latvia, Iceland, Mexico
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
Novartis Pharmaceuticals

Completed

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis (ASLeap)

Ankylosing Spondylitis

United States
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
Novartis Pharmaceuticals

Completed

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

Psoriatic Arthritis

United Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
Novartis Pharmaceuticals

Completed

First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks (FEATURE)

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Estonia, France, Canada
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE 1)

Ankylosing Spondylitis

Germany, Belgium, Netherlands, France, United States, Bulgaria, Italy, Russian Federation, Peru, United Kingdom, Canada, Mexico, Taiwan, Turkey
Novartis Pharmaceuticals

Completed

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA) (FUTURE 1)

Psoriatic Arthritis

Germany, United Kingdom, United States, Belgium, Philippines, Singapore, Thailand, Brazil, Czech Republic, Italy, Argentina, Israel, Russian Federation, Bulgaria, Romania, Australia, Canada, Poland, Slovakia
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) (REPLENISH)

Polymyalgia Rheumatica

United States, Australia, Germany, Belgium, France, Spain, Italy, Lebanon, Switzerland, Japan, Israel, Argentina, Netherlands, Colombia, Chile, Hungary, Poland, Turkey, Czechia, Brazil, South Africa, Mexico, Canada, Denmark, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Plaque Psoriasis

China, Thailand, Philippines, Turkey, Hungary, Malaysia
Novartis Pharmaceuticals

Completed

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

Psoriatic Arthritis

United States, Puerto Rico
Wake Forest University Health Sciences
Novartis

Withdrawn

Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

Pyoderma Gangrenosum
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
Novartis Pharmaceuticals

Completed

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis (MEASURE4)

Spondylitis, Ankylosing

Germany, Austria, Denmark, United States, Australia, Netherlands, Poland, Italy, Bulgaria, Spain, Russian Federation, United Kingdom, Greece, Czechia, Canada, Norway, Slovakia, Switzerland, Finland
Novartis Pharmaceuticals

Recruiting

Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)

Giant Cell Arteritis (GCA)

United States, Austria, Spain, Belgium, Greece, Hungary, Turkey, France, Israel, Australia, Switzerland, Germany, Denmark, Argentina, Finland, United Kingdom, Brazil, Chile, Portugal, Poland, Bulgaria, Czechia, Guatemala, Italy, Estonia, ... and more
Novartis Pharmaceuticals

Completed

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM)

Ankylosing Spondylitis

Germany
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Completed

First in Human Study of M4344 in Participants With Advanced Solid Tumors

Solid Tumor | Advanced Solid Tumor

Spain, United States, Netherlands, United Kingdom
Rigel Pharmaceuticals

No longer available

Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP

Immune Thrombocytopenic Purpura
Warner Chilcott

Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Erectile Dysfunction

United States
Impax Laboratories, LLC

Completed

Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease

Idiopathic Parkinson's Disease

United States
AstraZeneca
Parexel

Active, not recruiting

AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA)

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

Belgium, United States, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Italy, Korea, Republic of, Brazil, Japan, Turkey, China, Malaysia, Germany, Spain, Australia, Hungary, Portugal, Switzerland, Israel, Philippines, Russian... and more
Novartis Pharmaceuticals

Withdrawn

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound (INTERCEPT)

Psoriasis
Cytokinetics
Astellas Pharma Global Development, Inc.

Completed

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States, Canada
Lexicon Pharmaceuticals

Completed

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Healthy

Egypt
Massachusetts General Hospital

Completed

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Attention Deficit Hyperactivity Disorder

United States
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Novartis Pharmaceuticals

Completed

Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis (VIP-S)

Chronic Plaque Psoriasis

United States
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Novartis Pharmaceuticals

Completed

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus (PRELUDE)

Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Germany, United States, France
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
Professor Mikkel Østergaard
Novartis Healthcare A/S

Unknown

Treat-to-target With Secukinumab in Axial Spondyloarthritis (TRACE)

Ankylosing Spondylitis | Axial Spondyloarthritis

Denmark
NeuroBo Pharmaceuticals Inc.

Completed

Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers

Hypercholesterolemia
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Warner Chilcott

Completed

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Postmenopausal Osteoporosis

United States
Georgetown University

Unknown

Nilotinib in Huntington's Disease (Tasigna HD)

Huntington Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis

Chronic Plaque Type Psoriasis

Germany, United States, Belgium, Korea, Republic of, Spain, Taiwan, Australia, Austria, Italy, Estonia, Israel, Bulgaria, Netherlands, France, Switzerland, Portugal, Slovakia, Norway, United Kingdom, Hungary, Turkey, Canada, Denmark, ...
Novartis Pharmaceuticals

Terminated

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Asthma

Germany, Belgium, South Africa, United States, Russian Federation, France, Slovakia, Spain, Thailand, Czechia, Greece, Argentina, Peru, United Kingdom, Bulgaria, Turkey, Hungary, Vietnam, Philippines, Colombia, Chile
Bausch Health Americas, Inc.

Completed

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Psoriasis
Novartis Pharmaceuticals

Completed

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar) (SURPASS)

Ankylosing Spondylitis

Taiwan, Netherlands, United Kingdom, Germany, Korea, Republic of, Israel, United States, Belgium, Greece, Philippines, Russian Federation, Spain, Turkey, Portugal, Mexico, Peru, Denmark, France, Czechia, Australia, Canada, Poland, J... and more
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Serbia, Greece, Ukraine
AstraZeneca

Completed

Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration (AZD6765)

Major Depressive Disorder

United Kingdom
Reata, a wholly owned subsidiary of Biogen
AbbVie; Friedreich's Ataxia Research Alliance

Active, not recruiting

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Friedreich Ataxia

United States, Australia, Austria, Italy, United Kingdom
Novartis Pharmaceuticals

Completed

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

Dry Eye

United States

Search clinical trials for: secukinumab 150 mg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burkina Faso

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations